DAUNOMYCIN IN THE TREATMENT OF EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY - EFFECTIVE DOSES INVITRO AND INVIVO

  • 1 January 1985
    • journal article
    • research article
    • Vol. 26  (5) , 719-725
Abstract
Daunomycin, an anthracycline antibiotic, when injected into the vitreous effectively controls experimental proliferative vitreoretinopathy. By administering daunomycin intravitreally it is possible to achieve in vivo concentrations that prevent fibroblast proliferation in vitro. The 1/2-life of daunomycin in the vitreous is 131 min, indicating that a critical concentration is maintained in the eye for longer than 4 h after a single injection. Using 3H-daunomycin, the drug is eliminated across the retina; no significant binding of the drug to vitreous components occurs. It is possible to define the kinetics of drugs injected into the vitreous; a knowledge of the distribution of any drug in ocular tissues is necessary to effectively determine whether such drug is of therapeutic value.